Evidence map›Paper›PMID 41928993›Full record

ArticlebioRxiv : the preprint server for biology2026

Integrated 5-HT

Marco Taddei-Tardón, Lidia Medina-Rodríguez, Jessica L Maltman, Sarah Hudson, Sritanvi Potukanuma, Javier Hidalgo Jiménez, Sandra M Martín-Guerrero, Javier González-Maeso, Juan F López-Giménez

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Marco Taddei-TardónORCID 0009-0005-7966-6407
Lidia Medina-RodríguezORCID 0009-0006-2566-880X
Jessica L Maltman
Sarah Hudson
Sritanvi PotukanumaORCID 0009-0005-9337-3889
Javier Hidalgo Jiménez
Sandra M Martín-GuerreroORCID 0000-0003-1489-4757
Javier González-MaesoORCID 0000-0003-3105-3204
Juan F López-GiménezORCID 0000-0003-3021-6200

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents. However, the molecular mechanisms linking their acute hallucinogenic-like effects to longer-lasting neuroplastic responses remain incompletely understood, partly because of the scarcity of native neural models suitable for mechanistic studies. Here, we developed a neural stem cell-derived in vitro model capable of differentiating into neuronal and glial lineages and, after characterization, used it to investigate the molecular pharmacology of serotonergic psychedelics. A panel comprising tryptamines, phenethylamines and ergolines, including psychedelic compounds and selected non-psychedelic analogues, was evaluated alongside ketamine and TrkB agonists. Endpoints included dendritogenesis, synaptogenesis, immediate-early gene induction, BDNF expression and lactate production. TrkB silencing abolished dendritogenic responses to serotonergic psychedelics, ketamine and TrkB agonists, whereas 5-HT

Identifiers

PMID41928993
PMCPMC13042069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.